CN Patent

CN107344927A — Tafamidis葡甲胺盐的晶型E及其制备方法和用途

Assigned to Crystal Pharmatech Co Ltd · Expires 2017-11-14 · 9y expired

What this patent protects

本发明涉及Tafamidis葡甲胺盐的新晶型及其制备方法。相对于已知晶型，所述新晶型具有制备工艺更简单的性质。本发明还涉及包含所述新晶型的药物组合物、制剂以及它们在预防和/或治疗与治疗甲状腺素家族性淀粉样多发性神经病变相关疾病中的用途。

USPTO Abstract

本发明涉及Tafamidis葡甲胺盐的新晶型及其制备方法。相对于已知晶型，所述新晶型具有制备工艺更简单的性质。本发明还涉及包含所述新晶型的药物组合物、制剂以及它们在预防和/或治疗与治疗甲状腺素家族性淀粉样多发性神经病变相关疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107344927A
Jurisdiction
CN
Classification
—
Expires
2017-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.